Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 8 | 2014 | 358 | 0.650 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2010 | 88 | 0.590 |
Why?
|
| Noscapine | 1 | 2008 | 11 | 0.320 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2008 | 110 | 0.300 |
Why?
|
| Indoles | 3 | 2013 | 158 | 0.260 |
Why?
|
| Antineoplastic Agents | 6 | 2014 | 803 | 0.230 |
Why?
|
| Taxoids | 4 | 2013 | 37 | 0.200 |
Why?
|
| Caspase 3 | 3 | 2009 | 207 | 0.160 |
Why?
|
| Pyrazoles | 3 | 2010 | 85 | 0.150 |
Why?
|
| Sulfonamides | 3 | 2010 | 80 | 0.150 |
Why?
|
| Mice, Nude | 4 | 2013 | 337 | 0.140 |
Why?
|
| Mice | 11 | 2014 | 5913 | 0.130 |
Why?
|
| Annexin A2 | 1 | 2014 | 6 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2013 | 259 | 0.120 |
Why?
|
| Lung | 3 | 2014 | 446 | 0.120 |
Why?
|
| Apoptosis | 5 | 2009 | 1398 | 0.120 |
Why?
|
| Anisoles | 1 | 2013 | 3 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 78 | 0.110 |
Why?
|
| Haloperidol | 2 | 2010 | 26 | 0.110 |
Why?
|
| RNA Interference | 1 | 2014 | 243 | 0.110 |
Why?
|
| Phenols | 1 | 2013 | 80 | 0.110 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 409 | 0.100 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2009 | 78 | 0.100 |
Why?
|
| Drug Synergism | 2 | 2009 | 177 | 0.100 |
Why?
|
| Animals | 12 | 2014 | 15081 | 0.100 |
Why?
|
| Droperidol | 1 | 2010 | 3 | 0.090 |
Why?
|
| Bromocriptine | 1 | 2010 | 7 | 0.090 |
Why?
|
| Butyrophenones | 1 | 2008 | 5 | 0.080 |
Why?
|
| Azepines | 1 | 2008 | 17 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 421 | 0.080 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2008 | 77 | 0.080 |
Why?
|
| Antipsychotic Agents | 1 | 2008 | 68 | 0.080 |
Why?
|
| Cell Line, Tumor | 5 | 2014 | 2231 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 152 | 0.070 |
Why?
|
| Prostaglandin D2 | 1 | 2007 | 27 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2007 | 45 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2007 | 53 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 213 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2006 | 30 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2014 | 77 | 0.060 |
Why?
|
| Ionophores | 1 | 2003 | 12 | 0.060 |
Why?
|
| Monensin | 1 | 2003 | 4 | 0.060 |
Why?
|
| Immunotoxins | 1 | 2003 | 12 | 0.060 |
Why?
|
| Female | 8 | 2013 | 20969 | 0.060 |
Why?
|
| Transplantation, Heterologous | 3 | 2007 | 90 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 502 | 0.050 |
Why?
|
| Lipids | 2 | 2014 | 235 | 0.050 |
Why?
|
| Administration, Inhalation | 2 | 2010 | 80 | 0.040 |
Why?
|
| Aerosols | 2 | 2010 | 48 | 0.040 |
Why?
|
| Drug Interactions | 2 | 2010 | 141 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2009 | 122 | 0.040 |
Why?
|
| Molecular Structure | 2 | 2010 | 492 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2007 | 133 | 0.030 |
Why?
|
| Dinoprostone | 2 | 2006 | 63 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2010 | 1618 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2013 | 52 | 0.030 |
Why?
|
| Permeability | 1 | 2013 | 67 | 0.030 |
Why?
|
| Neoplasms | 1 | 2003 | 1103 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 161 | 0.030 |
Why?
|
| Humans | 6 | 2014 | 37093 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 222 | 0.030 |
Why?
|
| Rats | 2 | 2010 | 3483 | 0.030 |
Why?
|
| Reference Standards | 1 | 2010 | 52 | 0.020 |
Why?
|
| Dosage Forms | 1 | 2010 | 2 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 864 | 0.020 |
Why?
|
| Biological Availability | 1 | 2010 | 88 | 0.020 |
Why?
|
| Drug Stability | 1 | 2010 | 116 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2010 | 71 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2014 | 1207 | 0.020 |
Why?
|
| Particle Size | 1 | 2010 | 215 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 208 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 202 | 0.020 |
Why?
|
| Apomorphine | 1 | 2008 | 13 | 0.020 |
Why?
|
| Clozapine | 1 | 2008 | 17 | 0.020 |
Why?
|
| Lethal Dose 50 | 1 | 2008 | 30 | 0.020 |
Why?
|
| Stereotyped Behavior | 1 | 2008 | 22 | 0.020 |
Why?
|
| Nanostructures | 1 | 2010 | 134 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 661 | 0.020 |
Why?
|
| Male | 3 | 2014 | 20025 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 677 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 409 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 62 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2006 | 60 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2010 | 318 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 623 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 893 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 251 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2003 | 150 | 0.010 |
Why?
|
| Liposomes | 1 | 2003 | 118 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 807 | 0.010 |
Why?
|